Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Work In Process (2016 - 2025)

Ocular Therapeutix (OCUL) has 12 years of Work In Process data on record, last reported at $1.7 million in Q4 2025.

  • For Q4 2025, Work In Process rose 15.58% year-over-year to $1.7 million; the TTM value through Dec 2025 reached $1.7 million, up 15.58%, while the annual FY2025 figure was $1.7 million, 15.58% up from the prior year.
  • Work In Process reached $1.7 million in Q4 2025 per OCUL's latest filing, up from $1.4 million in the prior quarter.
  • Across five years, Work In Process topped out at $1.8 million in Q1 2025 and bottomed at $402000.0 in Q1 2021.
  • Average Work In Process over 5 years is $995800.0, with a median of $907000.0 recorded in 2022.
  • Peak YoY movement for Work In Process: skyrocketed 650.67% in 2021, then decreased 2.93% in 2025.
  • A 5-year view of Work In Process shows it stood at $605000.0 in 2021, then soared by 48.6% to $899000.0 in 2022, then rose by 12.57% to $1.0 million in 2023, then surged by 47.13% to $1.5 million in 2024, then increased by 15.58% to $1.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Work In Process were $1.7 million in Q4 2025, $1.4 million in Q3 2025, and $1.7 million in Q2 2025.